Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma

Exclusion Criteria

• •Have any active infection that is not treated
• •Be unable to perform any of the assessments required for endpoint analysis.
• •currently receive (or have received within four weeks of screening) experimental agents for the treatment of asthma
• •be actively listed (or expecting to be listed in the near future) for transplant of any organ
• •Have clinically important abnormal screening laboratory values : blood screening tests (Hematology, Chemistry, CBC including Eosinophil count) results that are not within normal limits (according to UMHC Laboratory Reference Ranges) Have a serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study
• •Have known allergies to penicillin or streptomycin
• •Be an organ transplant recipient
• •Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma
• •Have a non-pulmonary condition that limits lifespan to less than a year.
• •Have a history of drug or alcohol abuse within the past 24 months.
• •Be serum positive for HIV, hepatitis BsAg or Viremia hepatitis C
• •Be currently participating (or have participated within the previous 30 days) in an investigational therapeutic or device trial.
• •Have hypersensitivity to dimethyl sulfoxide (DMSO)
• •Have a resting oxygen saturation (SpO2) on room air of more than 93% at sea level or more than 88% at an altitude above 5,000 feet above sea level (1524 meters)